[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053899":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":87,"collaborators":11,"id":89,"slug":11,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":90,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":11,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Centre Jean Perrin","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"cDNA detection","EXPERIMENTAL",null,[13],"Biological: blood sampling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","blood sampling","The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy",[9],[21],{"name":22,"affiliation":5,"role":23},"Maureen BERNADACH Coordinator, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Angeline GINZAC COUVÉ Project manager, PhD","CONTACT","0463663337","+33","angeline.ginzac@clermont.unicancer.fr",[32,50,65,76],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"CH Henri Mondor Aurillac","RECRUITING","Aurillac","CANTAL","15000","France",{"type":40,"coordinates":41},"Point",[42,43],2.43983,44.92539,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":48,"phoneExt":11,"email":49},"Daniela BURLACU, Dr","0471465613","d.burlacu@ch-aurillac.fr",{"facility":51,"status":34,"city":52,"state":53,"zip":54,"country":38,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Centre Jean PERRIN","Clermont-Ferrand","Puy-de-Dôme","63011",{"type":40,"coordinates":56},[57,58],3.08682,45.77969,{"lat":58,"lon":57},[61,63],{"name":62,"role":27,"phone":28,"phoneExt":29,"email":30},"Angeline GINZAC Project manager, PhD",{"name":22,"role":64,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":66,"status":34,"city":67,"state":11,"zip":11,"country":38,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Hôpital de la Croix-Rousse","Lyon",{"type":40,"coordinates":69},[70,71],4.84789,45.74906,{"lat":71,"lon":70},[74],{"name":75,"role":64,"phone":11,"phoneExt":11,"email":11},"Philippe CÉRUSE, Pr",{"facility":77,"status":34,"city":78,"state":11,"zip":11,"country":38,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"CHU de Saint-Étienne","Saint-Etienne",{"type":40,"coordinates":80},[81,82],4.39,45.43389,{"lat":82,"lon":81},[85],{"name":86,"role":64,"phone":11,"phoneExt":11,"email":11},"Yann LELONGE, Dr",{"type":88,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100053899",false,"NCT07178847","cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas","Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma","NeckTAR-IN","Selection Criteria:\n\n* Patient included in NeckTAR study\n* Written informed consent signed for NeckTAR-IN study\n* Affiliation to the French social security system","ALL","18 Years","80 Years",{"count":100,"type":101},59,"ESTIMATED","INTERVENTIONAL",[104],"NA","The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.\n\nThe main question it aims to answer is :\n\n\\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).\n\nParticipants will :\n\n* be included in the main study (Neck-TAR)\n* have a blood sample 1 and 3-month after the end of treatment",[107],"Locally Advanced Head and Neck Carcinoma",[109,110],"circulating DNA","residual disease","2026-07-10",{"date":113,"type":114},"2026-07-13","ACTUAL",{"date":116,"type":114},"2025-10-13",{"date":118,"type":101},"2031-07",{"name":5,"class":6},4]